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Abstract Mitochondrial disease is complex and variable,
making diagnosis and management challenging. The situ-
ation is complicated by lack of sensitive outcomes of dis-
ease severity, progression, contributing pathology and
clinical efficacy. Gait is emerging as a sensitive marker of
pathology; however, to date, no studies have quantified gait
in mitochondrial disease. In this cross-sectional study, we
quantified gait characteristics in 24 patients with geneti-
cally confirmed mitochondrial disease (m.3243A[G and
m.8344A[G) and 24 controls. Gait was measured using an
instrumented walkway according to a predefined model
with five domains hypothesised to reflect independent
features of the neural control of gait in mitochondrial dis-
ease, including: pace (step velocity and step length);
rhythm (step time); variability (step length and step time
variability); asymmetry (step time asymmetry); and
postural stability (step width, step width variability and step
length asymmetry). Gait characteristics were compared
with respect to controls and genotype. Additional measures
of disease severity, pathophysiology and imaging were also
compared to gait to verify the validity of gait characteris-
tics. Discrete gait characteristics differed between controls
and mitochondrial disease groups, even in relatively mildly
affected patients harbouring the m.3243A[G mutation. The
pattern of gait impairment (increased variability and
reduced postural control) was supported by significant
associations with measures of disease severity, progression,
pathophysiology and radiological evidence of cerebellar
atrophy. Discrete gait characteristics may help describe
functional deficits in mitochondrial disease, enhance mea-
sures of disease severity and pathology, and could be used
to document treatment effects of novel therapies.
Keywords Mitochondrial disease  Gait  Disease
severity  Genotype  Cerebellum
Introduction
Mitochondrial disorders are one of the commonest inher-
ited neuromuscular disorders and present with a highly
variable and complex pattern of neurological and systemic
involvement [1]. Whilst progress has been made identify-
ing definitive genotypes in mitochondrial diseases, this is
of limited help to the clinician or patient because of con-
siderable heterogeneity in phenotype, which can be only
partly explained by the level of mutant and wild type
mtDNA present (heteroplasmy). Phenotypic heterogeneity
is reflected by the highly variable presentation of clinical
features [2]. The relationship between clinical outcomes,
genotype and heteroplasmy is therefore complex and
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current clinical outcomes do not accurately discriminate for
genotype or heteroplasmy, thereby limiting understanding
of disease evolvement, underlying pathology and appro-
priate interventions. A recent Cochrane review echoes this
sentiment concluding that there was no clear evidence to
support the use of any intervention in mitochondrial dis-
orders with heterogeneity in outcome measures limiting
comparison between trials [3].
Gait is emerging as a powerful measurement tool to
identify markers of incipient pathology, inform diagnostic
algorithms and disease progression, and measure efficacy
of interventions [4]. Discrete features of gait (such as
variability in the magnitude of stride to stride fluctuations)
are highly sensitive to the effects of ageing and pathology
[5–7], including incipient pathology associated with
increased genetic risk factors, making gait a potentially
useful metric to aid the neurologist [8, 9]. To date however
no studies have carried out a detailed quantification of gait
in patients with mitochondrial disease.
We therefore aimed to (1) describe the pattern of gait
impairments in patients with different genetic variants of
mitochondrial disease; and (2) explore the relationships
between gait characteristics with measures of mitochon-
drial disease severity, its underlying pathophysiological
consequences (such as myopathy and cerebellar atrophy)
and clinical and pathological measures. We, firstly,
hypothesised that gait characteristics would differ between
mitochondrial disease and control groups. Secondly, we
hypothesised that the pattern of deficit in gait would differ
with respect to genotype. Thirdly, gait characteristics
would be selectively associated with underlying markers of
disease (heteroplasmy) and its pathological consequences
(e.g., muscle weakness and ataxia). Lastly, we dichoto-
mised a subgroup of the cohort for presence (or absence) of
cerebellar atrophy as shown on MR and compared the gait
characteristics of both groups to verify our findings.
Subjects and methods
Subjects and study design
Patients with mitochondrial disease due to either the
m.3243A[G (18 patients) or 8344A[G mutations were
recruited from a mitochondrial outpatient clinic as part of
an exercise intervention study and had to be able to per-
form the walking assessment safely. We aimed to recruit
12 people each in the two arms of the intervention. Sample
size estimates for the exercise study were based on a
change in peak oxygen consumption following a similar
exercise intervention, allowing for 25 % attrition [10]. A
convenience sample of age-matched and sex-matched
control participants was also recruited. Ethical approval
was provided by the Sunderland Research Ethics Com-
mittee, United Kingdom, and written informed consent was
obtained from participants prior to testing.
Demographic, clinical and pathological measures
Age, sex, and height were recorded for all participants.
Disease severity was assessed using the Newcastle Mito-
chondrial Disease Adult Scale (NMDAS) [11], a validated
measure of disease burden and surrogate for phenotypic
severity, prospectively at the time of gait measurement.
Mitochondrial mutation load was assessed using urinary
epithelial cells [12]. Physiological markers of mitochon-
drial disease were collected as part of a larger exercise
study (manuscript in preparation) as follows: (1) energy
expenditure was assessed using a body-worn multi-sensor
array (SenseWear Pro3, Bodymedia Inc, Pennsylvania,
USA 2.5), which was worn by the participant for seven
days in the community; (2) exercise capacity (peak oxygen
consumption) was evaluated using cardiopulmonary exer-
cise testing, which was performed as previously reported
[13] (During all visits, a stepped incremental workload test
(*10–20 W/min) was conducted to elicit a symptom-
limited maximum oxygen uptake and heart rate response);
(3) muscle strength testing evaluated hip flexor and
extensor strength and was performed by the same investi-
gator (JN) using an isokinetic dynamometer (CSMI HU-
MACÒ/NORM testing and rehabilitation system) at a speed
of 60°/s [ 14]. (Participants underwent familiarization with
six sub-maximal contractions and then performed six
maximal repetitions with consistent verbal encourage-
ment); and (4) where available, brain MRI images were
reviewed (GSG) for the presence or absence of global
cerebellar atrophy retrospectively. GSG was blinded to the
gait results but not genotype at the time of assessment.
Quantitative gait assessment
Gait was assessed within a week of the clinical and patho-
logical measures in a gait laboratory setting. Participants
performed a block of three 12 mwalks at their ‘‘comfortable
walking pace.’’ Gait was assessed using a 7 m long 9 0.6 m
wide instrumented mat (Platinum model Gaitrite, software
version 4.5, CIR systems, USA). The mat was placed in the
centre of the walkway to ensure participants were walking at
a steady speed whilst gait was measured. Previous studies
have verified the Gaitrite mat to be a valid and reliable
method formeasuring gait [15]. Description of themethod of
calculating gait characteristics is reported in detail elsewhere
[16]. Gait variability was calculated from standard deviation
of left and right steps, which were then combined, and gait
asymmetry was calculated as the absolute difference
between left and right steps.
74 J Neurol (2014) 261:73–82
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Data processing and analysis
We quantified gait according to a predefined model with
five domains hypothesised to reflect independent features
of the neural control of gait, which provided a theoret-
ical framework to describe the features of gait associated
with mitochondrial disease and its genotypes [17] and
included: pace (step velocity and step length); rhythm
(step time); variability (step length and step time vari-
ability); asymmetry (step time asymmetry); and postural
stability (step width, step width variability and step
length asymmetry). Data for individual steps for each
condition were extracted from the Gaitrite database using
Microsoft Access 2007.
Statistics
Non-parametric Kruskal-Wallace tests were used to test
for group differences in gait characteristics. Post-hoc
Mann–Whitney U tests were considered significant if
p\ 0.05 after Holm–Bonferroni corrections. Associations
between gait and disease severity, mutation load, and
pathophysiological variables were assessed using Spear-
man Rho correlations. To avoid misleading findings, we
limited our correlation analysis between gait and the
NMDAS to the total NMDAS and exercise tolerance,
gait stability, cerebellar ataxia, and myopathy subscales.
To accommodate for multiple correlations, only correla-
tions with a p\ 0.01 were considered statistically
significant.
Results
Sixty people who attended a specialist outpatient clinic
were invited to participate in an exercise study for mito-
chondrial disease. Of these, four were ineligible because
they were unable to undergo an MRI, and one person had a
recent fracture. Eleven did not wish to participate because
of time commitments or ill health, and 21 failed to reply.
All 24 who consented went on to be tested. Of the 24
patients with mitochondrial disease, 18 patients presented
with the m.3243A[G mutation and six patients with the
m.8344A[G mutation. We also tested 24 age-matched and
sex-matched controls. Participant demographic and clinical
descriptors are presented in Table 1. Both the score on the
NMDAS (p = 0.023) and urinary mutation load
(p = 0.001) was significantly lower for m.3243A[G than
for m.8344A[G. People with mitochondria disease also
demonstrated reduced community energy expenditure
(p = 0.001), exercise capacity (p = 0.001) and hip flexion
(p = 0.002) and extension (p = 0.003) strength compared
to controls.
Gait deficits associated with mitochondrial disease
Compared to controls, patients with mitochondrial disease
had significantly reduced gait speed, step length and
increased variability in step time, step length and step
width (Table 2; Fig. 1). When described by genotype;
however, a more selective picture emerged. Patients with
the m.8344A[G mutation were globally impaired for all
gait characteristics except cadence, step width and step
length asymmetry compared to both the control and
m.3242A[G group (Table 2; Fig. 1). Patients with the
m.3243A[G mutation had a significantly shorter step
length and increased variability in step time and step width
compared to controls.
Relationship of gait and clinical burden of disease
Higher clinical disease burden (NMDAS) correlated with
reduced walking speed, step length, and increased step
width variability and step length asymmetry. The pattern of
association was different for the individual subscales with
additional features emerging in respect to variability and
asymmetry (Table 3).
Relationship of gait with pathophysiological burden
of disease
We explored gait characteristics with respect to a battery of
pathophysiological markers of mitochondrial disease
(mutation load, energy expenditure, exercise capacity
[peak oxygen consumption], and muscle strength)
(Table 4). For this analysis, we concentrated on the
m.3242A[G group because we were interested in those
characteristics that were sensitive to early subtle impact of
disease independent of the compensatory changes observed
in the m.8344A[G group. Increased mutation load was
significantly associated with increased step time asymme-
try and step width variability (Table 4). The relationship
between gait and energy expenditure, peak exercise
capacity and muscle strength was less clear. There were
moderate correlations between reduced step length and
velocity (consistent with an independent domain of gait
representing pace); and impaired muscle strength (hip
flexors and extensors), peak exercise capacity and energy
expenditure; however, several of these did not reach sta-
tistical significance. No other variables were related to the
physiological characteristics.
Structural magnetic resonance brain images were
available for 13 of the 24 mitochondrial participants.
Because there were fewer participants with available
imaging, we pooled both genotypes to explore the rela-
tionship of cerebellar atrophy as a marker of ataxia and gait
characteristics. Cerebellar atrophy was defined if the
J Neurol (2014) 261:73–82 75
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cerebellum was small with shrunken folia and large cere-
bellar fissures. Of those subjects four were the m.8344A[G
genotype and all had cerebellar atrophy while nine repre-
sented the m.3243A[G genotype and of those six had
evidence of atrophy. Participants with cerebellar atrophy
walked with significantly greater step width (p = 0.049),
step width variability (p = 0.049), and step length asym-
metry (p = 0.014), consistent with domains of gait that
represent postural control and variability.
Discussion
To our knowledge, this is the first study to quantify gait in
genetically confirmed mitochondrial disease. We used a
robust model to capture the complexity of gait, which
enabled us to differentiate mitochondrial genotypes and
identify the pattern of gait deficits potentially reflecting
differences in the underlying pathophysiology and neural
control of locomotion. Our findings confirm our hypotheses
and show that gait differed in a sensitive and selective
manner with respect to mitochondrial disease and genotype
even in relatively mildly affected patients with
m.3243A[G. Associations with clinical disease burden as
assessed by NMDAS and pathophysiological markers
support the use of gait as a robust clinical measure of
disease severity.
Gait deficits associated with mitochondrial disease
and genotype
Gait impairment was observed in both the mitochondrial
disease group and individual genotypes compared to con-
trols. The m.8344A[G genotype was globally impaired in
all gait characteristics except cadence, step width and step
length asymmetry which is possibly not surprising given
the very marked impairment of physical function and high
level of clinical symptoms present in this group. In con-
trast, fewer gait characteristics differed between the
m.3243A[G genotype and controls reflecting their higher
level of performance whilst highlighting difficulties main-
taining adequate pace (step length), low magnitude of
variability (step time variability) and postural control (step
width variability) when walking [16]. These results also
suggest that different pathological processes may underpin
gait impairments such that even patients with the least
severe m.3243A[G genotype could be differentiated on the
basis of their gait characteristics.
Does gait reflect the burden of disease?
We explored the associations between gait and clinical
disease severity (NMDAS) for the total mitochondrialT
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disease group (m.8344A[G and m.3243A[G). Patients
with more severe symptoms (NMDAS) had greater gait
impairment. Some of the gait characteristics that differed
between people with mitochondrial disease and controls
were different from those associated with the NMDAS
suggesting caution in selection of outcomes, if the purpose
of gait is to provide a correlate of disease severity. Gait
speed, step length, and step width variability, however,
were both sensitive to group differences and are associated
with the NMDAS, guiding variable selection. Associations
were observed for gait outcomes with exercise, gait and
cerebellar sub-scales of the NMDAS, highlighting the
underlying pathological contribution. The association
between gait and the myopathy subscale was not so clear
with gait asymmetry emerging as the only significant
characteristic, which was surprising and difficult to
explain. The six-item myopathy subscale features both
upper and lower limb ratings, which may explain the poor
association.
Does gait reflect the pathological consequences
of mitochondrial disease?
We were interested to explore the relationship between gait
characteristics and the underlying pathophysiology (het-
eroplasmy), ataxia, muscle strength, and peak exercise
Fig. 1 Individual and group gait performance. The solid bar
represents the median value with individual scores displayed around
the median. *Indicates a significant difference compared to control
participants.  Indicates a significant difference between m.3243 and
m.8344 genotypes. A p value of B0.05 after Holm–Bonferroni
corrections was considered significant
J Neurol (2014) 261:73–82 79
123
capacity). The m.3243A[G genotype had high performing
individuals (as determined by normal gait speed), and the
gait impairments, therefore, most likely reflect the primary
features of mitochondrial disease rather than compensatory
changes related to reduced mobility. In contrast, the more
global gait deficits in the m.8344A[G genotype reflect a
combination of primary disease, deconditioning and com-
pensation. We, therefore, focussed on the m.3243A[G
genotype to explore the pathophysiological consequences
of mitochondrial disease and used a model of gait as a
theoretical framework to interpret the pattern of deficit with
respect to their pathophysiological correlates.
Gait performance was significantly related to hetero-
plasmy for discrete characteristics (increased step width
variability and step time asymmetry). Step width
variability was also significantly greater in this group
compared to controls. It is possible that these discrete
features of gait reflect the underlying central pathological
disease burden warranting further investigation.
Ataxia was also a common clinical symptom in this
cohort. Cerebellar dysfunction is a major cause of gait
ataxia and studies have shown that balance impairment and
increased variability of global and segmental gait charac-
teristics makes an important contribution [18–20]. Vari-
ability describes the magnitude of stride to stride
fluctuations in gait allowing smooth, consistent rhythmical
stepping movements. The cerebellum plays a role in con-
trol of timing and coordination of movement, making
increased variability a likely consequence of cerebellar
atrophy [21, 22]. Our findings support a role for cerebellar
Table 3 Correlation between gait performance, total NMDAS, and NMDAS subscales
Gait domain Gait variables NMDAS NMDAS subscale
Exercise tolerance Gait stability Myopathy Cerebellar ataxia
Pace Step velocity -0.632 (0.001) -0.733 (0.001) -0.569 (0.005) -0.393 (0.064) -0.425 (0.043)
Step length -0.567 (0.004) -0.744 (0.001) -0.599 (0.003) -0.472 (0.023) -0.377 (0.076)
Rhythm Cadence -0.409 (0.047) -0.525 (0.010) -0.417 (0.048) -0.074 (0.736) -0.311 (0.149)
Asymmetry Step time asymmetry 0.449 (0.028) 0.622 (0.002) 0.456 (0.029) 0.632 (0.001) 0.454 (0.030)
Variability Step length variability 0.353 (0.090) 0.501 (0.015) 0.463 (0.026) 0.214 (0.326) 0.545 (0.007)
Step time variability 0.161 (0.452) 0.412 (0.051) 0.347 (0.105) 0.067 (0.762) 0.531 (0.009)
Postural control Step width 0.394 (0.057) 0.424 (0.044) 0.438 (0.036) 0.357 (0.094) 0.453 (0.030)
Step width variability 0.616 (0.001) 0.320 (0.137) 0.613 (0.002) 0.339 (0.113) 0.635 (0.001)
Step length asymmetry 0.623 (0.001) 0.290 (0.179) 0.286 (0.186) 0.540 (0.008) 0.429 (0.041)
NMDAS Newcastle Mitochondrial Disease Adult Scale, subscales range from 0 to 5, with a higher score indicating more severe symptoms.
Significant correlations presented in italics (p B 0.01, two-tailed)
Table 4 Spearman Rho correlations between mutation load, energy expenditure, peak exercise capacity and muscle strength variables and gait
outcomes in people with Mitochondrial disorder
Gait
domain
Gait
variables
Mutation load
(%)
Community energy
expenditure (cals)
Exercise capacity (peak oxygen
consumption) (ml kg min)
Hip flexor
strength (nm/kg)
Hip extensor
strength (nm/kg)
Pace Step velocity -0.294 (0.164) 0.305 (0.157) 0.475 (0.019) 0.441 (0.045) 0.453 (0.039)
Step length -0.228 (0.285) 0.433 (0.039) 0.605 (0.002) 0.513 (0.017) 0.506 (0.019)
Rhythm Cadence -0.406 (0.049) -0.023 (0.918) 0.178 (0.405) 0.067 (0.773) 0.192 (0.404)
Asymmetry Step time
asymmetry
0.566 (0.004) -0.093 (0.673) -0.336 (0.109) -0.343 (0.128) -0.457 (0.037)
Variability Step length
variability
0.383 (0.064) -0.186 (0.396) -0.209 (0.328) -0.182 (0.430) -0.173 (0.454)
Step time
variability
0.154 (0.474) -0.256 (0.239) -0.154 (0.473) -0.318 (0.159) -0.203 (0.378)
Postural control Step width 0.090 (0.674) 0.201 (0.359) -0.003 (0.990) -0.069 (0.767) -0.021 (0.929)
Step width
variability
0.605 (0.002) 0.069 (0.754) -0.165 (0.440) -0.333 (0.140) -0.288 (0.205)
Step length
asymmetry
0.392 (0.058) 0.078 (0.723) -0.319 (0.129) -0.181 (0.431) -0.206 (0.369)
Significant correlations presented in italics (p\ 0.05, two-tailed)
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atrophy underpinning gait disturbance in mitochondrial
disease. We found selective early changes in the generation
of consistent steps leading to increased step time variabil-
ity. In addition, increased step width variability reflects
lateral instability and is implicated as a marker of impaired
postural control consistent with our gait model and findings
in older adults [17, 23]. Given the clinical presentation of
these genotypes [2] in our group, it is highly likely that
muscle pathology and ataxia either in isolation or in
combination contribute in a selective manner to gait
reflected in the subtle changes observed. This is also sub-
stantiated by significant correlations with cerebellar
domains of the NMDAS, selective association with muta-
tion load and evidence of increased cerebellar atrophy from
a subset of participants for whom MR data was available.
Muscle strength is reflected in gait by step length, which
determines the ability to maintain an adequate pace of
locomotion. Reduced step length is, therefore, most likely a
consequence of muscle weakness and myopathy. This is
reinforced by the significant association of peak exercise
capacity with step length. Together these features suggest
an early and subtle contribution of muscle strength to
generation of an adequate pace of locomotion as repre-
sented by step length and walking speed.
Although this study is the first to provide a description
of gait impairment in patients with mitochondrial disease,
we still do not know how quickly gait deteriorates with
disease progression or how responsive gait impairments are
to potential therapeutic intervention. In addition, we were
only able to investigate gait impairment in two genotypes
and in very small numbers and so our findings should be
interpreted with this in mind and also may not extend to
patients with other genotypes. However, given that ataxia
is prevalent in our centre’s cohort of patients with mito-
chondrial disease with nearly one-third with documented
ataxia (267/945 patients) and, less than half of these cases
attributable to the genotypes under investigation here (71
patients harboring m.3243A[G mutation and 18 patients
harboring m.8344A[G mutation), we postulate that our
findings are transferrable to other genotypes, but further
assessment is required. Seven patients from the total group
had nerve conduction studies performed and out of these
only three had electrophysiological evidence of a sensory-
motor axonal neuropathy, and, although we concede that
evidence is limited, it is unlikely that neuropathy is a sig-
nificant contributor to the gait features identified. These
findings also enhance opportunities for early targeted
intervention at a time when there is a greater capacity to
comply with therapy and avoid secondary consequences of
disuse. In the absence of pharmacological evidence tar-
geted physical therapy, it could be useful to address gait
deficit early in the disease process when the deficits are
relatively mild [24].
As identified in a recent Cochrane review [3], identifica-
tion and harmonisation of sensitive outcomes is essential
across centres and trials. Gait deficits are associated with
mitochondrial disease and genotype in a selective fashion,
which seems to reflect the clinical burden of disease and its
pathological consequences. Furthermore, gait is easily
quantifiable and sensitive to change in other clinical popu-
lations, therefore, quantification of discrete gait character-
isticsmay enhance clinicalmeasures of disease severity such
as the NMDAS, pathology and efficacy of novel therapies.
Although this was a small study, the results are interesting
and warrant further longitudinal investigation as well as
examination into the influence of gait deficits in mitochon-
drial disease on mobility and falls in the community.
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